Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 70
Updated:3/17/2019
Start Date:April 27, 2017
End Date:January 1, 2021
Contact:Timothy Krepski
Email:tkrepsk1@fairview.org
Phone:612-273-2800

Use our guide to learn which trials are right for you!

Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)

This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a
short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting
chemotherapy (CY/FLU) in subjects with refractory or relapsed acute myelogenous leukemia
(AML). FATE-NK100 is a natural killer (NK) cell product that is enriched for NK cells with an
"adaptive", or human cytomegalovirus (CMV)-induced, phenotype. The NK cell product is
comprised of peripheral blood (PB) leukocytes sourced from a related donor
(HLA-haploidentical or better but not fully HLA-matched) that is seropositive for
cytomegalovirus (CMV+), and enriched for adaptive NK cells by depletion of CD3+
(T-lymphocytes) and CD19+ (B-lymphocytes) cells followed by ex-vivo culture expansion.


Inclusion Criteria:

- ≥18 but ≤ 70 years of age

- Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease
criteria:

* Primary induction failure:

** De Novo AML: no CR after 2, 3 or 4 induction attempts with high dose chemotherapy

- Secondary AML (from MDS or treatment related): no CR after 1, 2 or 3 cycles of
high dose chemotherapy

- Relapsed:

- Not in CR after 1 or 2 cycles of standard re-induction therapy

- Relapse diagnosed at the time of the 6 months post-HCT standard of care follow-up
or later (i.e. based on bone marrow biopsy performed Day +170 or later) and
without evidence of graft versus host disease (GVHD)

- For patients > 60 years of age, the minimum of 1 cycle of standard
chemotherapy is not required.

- Available HLA-matched or better but not fully HLA-matched (2/4 or 3/4 antigens)
related donor (aged 18 to 75 years) with donor/recipient match based on a minimum of
intermediate resolution DNA based Class I typing of the A and B locus who is CMV
seropositive.

- Karnofsky Performance Status ≥ 60%

- Adequate organ function within 14 days of study registration (28 days for pulmonary
and cardiac) defined as:

- Creatinine: Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73m^2 per
current institutional calculation formula

- Hepatic: AST and ALT ≤ 3 x upper limit of institutional normal

- Pulmonary Function: oxygen saturation ≥ 90% on room air; PFT's required only if
symptomatic or prior known impairment - must have pulmonary function >50%
corrected DLCO and FEV1

- Cardiac Function: LVEF ≥ 40% by echocardiography or MUGA

- No symptomatic active conduction system abnormalities

- Able to be off prednisone or other immunosuppressive medications for at least 3 days
prior to FATE-NK100 cell infusion (excluding preparative regimen premedications)

- Sexually active females of child bearing potential and males with partners of child
bearing potential must agree to use effective contraception during therapy and for 4
months after completion of therapy

- Voluntary written consent prior to the performance of any research related procedures

Arm Specific Inclusion Criteria

High-Risk aGVHD (ARM 1):

- Pediatric or adult (ages 0-76 years) HCT recipients with high-risk acute GVHD, as
determined either by the refined MN acute GVHD risk score [28]:
http://z.umn.edu/MNAcuteGVHDRiskScore OR high risk on the basis of blood biomarkers (Ann
Arbor Score 3) [31]. Patients in this arm must start treatment within the first 7 days
after onset of high-risk aGVHD.

or

Steroid- Dependent aGVHD (ARM 2A):

- Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid-dependent
acute GVHD, defined as any one of the following: Flare of acute GVHD of at least grade
II/IV severity within 8 weeks of tapering down or (off of) immunosuppression for acute
GVHD, with the flare occurring on ≤0.5 mg/kg prednisone. This can include late-onset aGVHD
and overlap syndrome.

or

Steroid-Refractory aGVHD (ARM 2B):

- Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid refractory
acute GVHD, defined as any one of the following:

- No response of acute GVHD after at least 4 days of systemic corticosteroids of at
least 2 mg/kg prednisone or equivalent

- Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2
mg/kg prednisone or equivalent

- Failure to improve to at least grade II acute GVHD after 14 days of systemic
corticosteroids, with initial doses of at least 2 mg/kg prednisone or equivalent

- Flare of acute GVHD of at least grade II/IV severity while on steroids at a dose
>0.5/mg/kg/day. This can include late-onset aGVHD and overlap syndrome.

Exclusion Criteria:

- Myocardial Infraction (MI) within the previous 6 months

- Acute leukemias of ambiguous lineage

- Pregnant or breastfeeding - The agents used in this study include those that fall
under Pregnancy Category D - have known teratogenic potential. Women of child bearing
potential must have a negative pregnancy test at screening

- History of or known active CNS involvement with AML

- Active autoimmune disease requiring systemic immunosuppressive therapy

- History of severe asthma and currently on chronic systemic medications (mild asthma
requiring inhaled steroids only is eligible)

- New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan
unless cleared for study by Pulmonary. Infiltrates attributed to infection must be
stable/improving (with associated clinical improvement) after 1 week of appropriate
therapy (4 weeks for presumed or documented fungal infections).

- Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active
hepatitis C/B - chronic asymptomatic viral hepatitis is allowed

- Received any investigational agent within the 14 days before the start of study
treatment (1st dose of fludarabine)
We found this trial at
1
site
Minneapolis, Minnesota 55455
Principal Investigator: Sarah Cooley, MD
Phone: 612-273-2800
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials